Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.
Current stock price: 17.85 pence, down 8.5% in London on Monday
12-month change: down 42%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.


(Alliance News) - Angle PLC - Guildford, England-based liquid biopsy company, which is to be renamed CelLBxHealth PLC - Appoints Peter Collins as inte...


(Alliance News) - Angle PLC shares fell on Wednesday, after it announced plans to rename itself CelLBxHealth PLC and "[pursue] a revised strategy", wi...


Angle PLC - Guildford, England-based liquid biopsy company - Says that, following talks with an unnamed "significant shareholder", Chief Executive Off...


LONDON (Alliance News) - UK shares have opened lower Thursday, following the decision of the US Federal Reserve to continue tapering its asset purchas...




Medical diagnostic device maker Angle has won European approval for a system used in the diagnosis and treatment of cancer patients. Angle said regul...


Specialist medtech company ANGLE has raised 6.2m pounds after realising its investment in graphics technology developer Geomerics, which it sold to AR...


Shares in Angle, a specialist medtech company, leapt 20 per cent on Monday after the group said it has extended the operational capability of its Pars...


Angle, an AIM-listed specialist medtech company, has initiated the launch of its Parsortix non-invasive cancer diagnostic product for the research mar...


Angle, a specialist medtech company, has placed 4.53m new ordinary shares at 50p each, representing a discount of 17.4 per cent on the mid-price of 60...


Medical technology firm Angle saw its shares jump for a second day in a row after it received cash due from the sale of its portfolio company Acoylte ...